Thus, IFN is widely clinically applied as a biological therapy to target hairy cell leukemia, chronic myelogenous leukemia, renal cell carcinoma and melanoma (10). This evidence concerns the gene IFNA1 and hereditary clear cell renal cell carcinoma.